
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. demonstrated robust financial performance, with the Global Spine segment achieving a notable 10% revenue growth, driven by strong market share capture and significant growth in several key product categories. Additionally, the US spinal fixation sector reported a 5% revenue increase, further indicating the company's competitive positioning within the orthopedic market. The company's longer-term outlook is bolstered by the expectation of continued growth in the bone growth therapy (BGT) business, projected to outpace market growth rates of 2% to 3% through strategic cross-selling initiatives.
Bears say
Orthofix Medical Inc. has illustrated a negative outlook due to disappointing long-term guidance, pushing its adjusted EBITDA margin target to 2028 and revealing lower-than-expected financial performance for 2026 and 2027. Despite achieving a revenue of $219.9 million, which exceeded estimates, the company's spinal implant and biologics revenue fell short, indicating potential weaknesses in key product areas such as 7D Flash Navigation and biologics. Additionally, the company's GAAP SG&A expenses were significantly higher than anticipated, further exacerbating concerns regarding operational efficiency and profitability.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares